一分钟看懂
这是一项关于卵巢癌的III 期研究，登记的药物或干预包括HS-20089+Bevacizumab；Dose 2：arboplatin+Paclitaxel+Bevacizumab；Dose 3：arboplatin+Gemcitabine+Bevacizumab；Dose 4：arboplatin+Doxorubicin Hydroc，当前状态为尚未开始招募。登记地点显示中国合肥、北京、重庆、厦门等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
HS-20089+Bevacizumab；Dose 2：arboplatin+Paclitaxel+Bevacizumab；Dose 3：arboplatin+Gemcitabine+Bevacizumab；Dose 4：arboplatin+Doxorubicin Hydrochloride Liposome+Bevacizumab · III 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Anhui Provincial Hospital · 合肥
- National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences · 北京
- Peking University Cancer Hospital · 北京
- Peking Union Medical College Hospital · 北京
- The First Affiliated Hospital of Chongqing Medical University · 重庆
- Chongqing University Cancer Hospital · 重庆
- The First Affiliated Hospital of Xiamen University · 厦门
- Sun Yat-sen University Cancer Center · 广州
- Yuebei People's Hospital · 韶关
- Guangxi Medical University Cancer Hospital · 南宁
- Harbin Medical University Cancer Hospital · 哈尔滨
- Anyang Cancer Hospital · 安阳
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 武汉
- Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology · 武汉
- Hubei Cancer Hospital · 武汉
- Hunan Cancer Hospital · 长沙
- Jiangsu Cancer Hospital · 南京
- Jiangsu Province Hospital · 南京
- Xuzhou Central Hospital · 徐州
- Jiangxi Maternal and Child Health Hospital · 南昌
- Jiangxi Cancer Hospital · 南昌
- The First Hospital of Jilin University · 长春
- The Second Hospital of Jilin University · 长春
- Shengjing Hospital of China Medical University · 沈阳
- Liaoning Cancer Hospital · 沈阳
- Shandong Cancer Hospital · 济南
- Qilu Hospital of Shandong University · 济南
- Linyi People's Hospital · 临沂
- Fudan University Shanghai Cancer Center · 上海
- Shanxi Cancer Hospital · 太原
- The First Affiliated Hospital of Xi'an Jiaotong University · 西安
- West China Second University Hospital, Sichuan University · 成都
- The Affiliated Hospital of Southwest Medical University · 泸州
- Tianjin Cancer Hospital · 天津
- Yunnan Cancer Hospital · 昆明
- The Second Affiliated Hospital of Zhejiang University · 杭州
- Zhejiang People's Hospital · 杭州
- Zhejiang Cancer Hospital · 杭州
- The First Affiliated Hospital of Wenzhou Medical University · 温州
公开的入选条件
- The main criteria are as follows:
- 1. Female, aged 18 years or older (≥18 years)
- 2. Willing to voluntarily participate in this clinical trial, understand the study procedures, and able to provide written informed consent
- 3. Platinum-sensitive recurrence
- 4. ECOG PS: 0-1
- 5. Expected survival of more than 12 weeks.
- 6. Women of childbearing potential must be willing to use appropriate contraceptive measures from the time of signing informed consent until 6 months after the last dose administration and should not be breastfeeding.
- 7. Must be able to provide sufficient fresh or archived tumor tissue specimens that meet the requirements.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07821606；登记信息更新于 2026-09-16。